| abstract |
The present inventionn n n n is 1 or 2,n n n p is 1 or 2,n n n R 1 is a halogen atom, trifluoromethyl radical; (C 1 -C 4 ) alkyl; (C 1 -C 4 ) alkoxy; Trifluoromethoxy radicals;n n n R 2 represents a hydrogen atom or a halogen atom;n n n R 3 Silver hydrogen atom; -OR 5 group; -CH 2 0R 5 group; -NR 6 R 7 group; -NR 8 COR 9 group; -NR 8 CONR 1O R 11 group; -CH 2 NR 12 R 13 group; -CH 2 NR 8 CONR 14 R 15 group; (C One -C 4 A) alkoxycarbonyl group; -CONR 16 R 17 Represents a group;n n n And R 3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring;n n n R 4 is An aromatic group selected from;n n n The aromatic group is unsubstituted or halogen atom; (C 1 -C 4 ) alkyl; (C 1 -C 4 ) alkoxy; A monocyclic piperazinylacylpiperidine derivative of the formula (I) substituted or monosubstituted with a substituent independently selected from trifluoromethyl radicals. The invention also relates to methods of preparing the compounds and their therapeutic uses. |